Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is identified as a promising investment opportunity in the biotech sector, with a recent price target adjustment by Deutsche Bank to $30 from $31, maintaining a Hold rating post Q4 fiscal report [1]. Financial Performance - For Q4 2025, Harmony Biosciences reported revenue of $243.8 million, reflecting a 21% year-over-year growth for its product WAKIX. The full-year net product revenue reached $868.5 million, showcasing six consecutive years of revenue growth and profitability [2]. - The company anticipates that WAKIX will exceed $1 billion in revenue and achieve blockbuster status by 2026, indicating strong market potential for the product [3]. Product and Market Position - WAKIX is a therapeutic product developed by Harmony Biosciences that enhances histamine signaling in the brain by binding to H3 receptors, aimed at treating neurological disorders [4]. - The average number of patients using WAKIX increased by approximately 400 to around 8,500 in fiscal Q4 2025, marking the third consecutive quarter of similar patient growth [3].

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same period last year, marking the highest quarterly revenues to date [4][23] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [5] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [24] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching approximately 8,500 average patients on WAKIX [4][10] - The approval of WAKIX for the treatment of cataplexy in pediatric patients aged six years and older is expected to enhance market penetration [12] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for continued growth of WAKIX [5] - The company anticipates WAKIX net revenue to reach blockbuster status of $1 billion-$1.04 billion in 2026, reflecting strong expectations for growth [25] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the next-generation pitolisant formulations, including pitolisant GR and pitolisant HD, targeting unique indications in orphan rare diseases [7][9] - The company is advancing a robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications, aiming for multiple catalysts over the next few years [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, supported by strong commercial execution and a clear growth strategy [9][28] - The company remains committed to defending its intellectual property and is optimistic about the potential for pediatric exclusivity for WAKIX [7][24] Other Important Information - Harmony ended Q4 2025 with approximately $882.5 million in cash equivalents and investments, providing financial flexibility for growth initiatives [23] - The company is expanding its field-based teams by nearly 20% to enhance market presence and support continued growth [11] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the emerging benefit-risk profile for EPX-100? - Management noted that patients in the Dravet syndrome study had treatment-resistant seizures, with a median reduction in seizures of approximately 50% and a favorable safety profile compared to other medications [30][32] Question: What is the timeline for the NDA submission for pitolisant GR? - The company is on track to submit the NDA for pitolisant GR in Q2 2026, with a target PDUFA date in Q1 2027 [52][53] Question: How is the company preparing for the pediatric cataplexy indication? - Management highlighted that the approval for pediatric cataplexy provides greater flexibility for healthcare providers and is expected to enhance the overall market opportunity for WAKIX [90][91] Question: What are the dynamics behind the increase in SG&A expenses in Q4? - The increase in expenses was primarily driven by R&D investments for ongoing Phase 3 studies and litigation-related costs [61][70]

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same period last year, marking the highest quarterly revenues to date [4][23] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [5] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [24] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching approximately 8,500 average patients on WAKIX [4][10] - The company is guiding WAKIX net revenue to blockbuster status of $1 billion-$1.04 billion for 2026, reflecting strong expectations for continued growth [5][25] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for WAKIX [5] - The recent FDA approval of WAKIX for the treatment of cataplexy in pediatric patients aged 6 years and older is expected to enhance market penetration [12] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the next-generation pitolisant formulations, including pitolisant GR and pitolisant HD, targeting unique indications in orphan rare diseases and broader CNS indications [7][9] - The company is advancing a robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications, aiming for multiple catalysts over the next few years [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, supported by strong commercial execution and a clear path for growth [9][28] - The company remains committed to defending its intellectual property and is optimistic about the potential for pediatric exclusivity for WAKIX [7][28] Other Important Information - Harmony ended Q4 2025 with approximately $882.5 million in cash equivalents and investments, providing financial flexibility for growth initiatives [23] - The company is expanding its field-based teams by nearly 20% to enhance market presence and support continued growth [11] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the baseline anti-seizure med use for EPX-100 in Dravet syndrome? - Management noted that patients had treatment-resistant seizures and comparable baseline seizure rates to other studies, with a median reduction in seizures of approximately 50% [30][32] Question: What is the PK, PD, and safety bar for the orexin 2 receptor agonist in phase 1 studies? - Management indicated that they expect to confirm the expected profile of once-daily dosing and are making progress towards advancing the program [38][39] Question: Can you clarify the increase in SG&A expenses in Q4? - The increase was primarily driven by R&D investments for phase 3 studies and litigation expenses related to ANDA settlements [60][62] Question: What is the timeline for decisions expected in ongoing litigation? - Management stated that the timeline for a ruling is uncertain, but they are confident in their position following recent settlements with generic filers [74][76]

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in Q4 2024, marking the highest quarterly revenues to date [3][22] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [4] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [23] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching about 8,500 average patients on the drug [3][4] - The company anticipates WAKIX net revenue to reach blockbuster status of $1 billion-$1.04 billion in 2026, driven by strong demand and market opportunity [4][10] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for continued growth of WAKIX [4] - The recent FDA approval of WAKIX for treating cataplexy in pediatric patients aged 6 years and older is expected to enhance market penetration [10][95] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the upcoming NDA submission for Pitolisant GR in Q2 2026 and a target PDUFA date in Q1 2027 [5][26] - The company is also exploring broader CNS indications with a new formulation of pitolisant, supported by newly licensed IP with patent protection until 2042 [6][17] - A robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications is in place, setting the stage for multiple catalysts [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, citing strong execution and market demand [4][26] - The company is well-positioned with a strong balance sheet, approximately $882.5 million in cash equivalents, to fund growth and pipeline advancements [22][24] Other Important Information - The company has settled with six of the seven ANDA filers regarding WAKIX, with generic entry not expected before March 2030 if pediatric exclusivity is granted [5][50] - Significant increases in R&D investments are anticipated as the company advances its pipeline, with five registrational studies ongoing and a sixth planned [25][63] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the emerging benefit-risk profile for EPX-100? - Management noted that patients in the Dravet syndrome study had treatment-resistant seizures, with a median reduction in seizures of approximately 50% and a favorable safety profile compared to other medications [30][32] Question: What is the PK, PD, and safety bar for the orexin 2 receptor agonist? - Management indicated that they expect to see clinical PK data by mid-2026 and are making progress towards advancing the program to the next stage of development [39][41] Question: Can you clarify the increase in SG&A expenses in Q4? - The increase was primarily driven by R&D investments for Phase 3 studies and litigation expenses related to ANDA settlements [62][63] Question: What is the timeline for decisions regarding ongoing litigation? - Management stated that the timeline for a ruling is uncertain, but they remain confident in their IP strength and the settlements achieved with generic filers [78][79]

Q4 & FY 2025 Financial Results & Business Update February 24, 2026 Copyright © 2026 Harmony Biosciences. All rights reserved. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations ...

Company Overview - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for narcolepsy [5] - The company reported a total revenue of $825.94 million and a net income of $185.68 million for the trailing twelve months (TTM) [4] - The company has 268 employees and experienced a 1-year price change of -5.92% as of January 31, 2026 [4] Recent Executive Transactions - Sandip Kapadia, the Chief Financial Officer, sold 3,746 shares on January 26, 2026, for approximately $139,171 [1][2] - Following this transaction, Kapadia's direct holdings decreased to 24,521 shares from over 127,000 shares in March 2023 [8] - The transaction value was based on a weighted average purchase price of $37.15, with a post-transaction value of $916,105 based on the market close of $37.36 [2] Financial Performance and Outlook - Harmony Biosciences expects to achieve over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [9] - The company has other medications in advanced development stages, projected to sustain operations into 2040 [10] - A 10% revenue increase is anticipated for 2025, indicating strong financial results and a positive outlook for investors [10] Investor Implications - Despite the recent sale by Kapadia, Harmony Biosciences' financials remain strong, particularly highlighted by a robust Q3 2025 net income, the highest since Q3 2022 [7] - The recent sale size of 3,746 shares is significantly below Kapadia's median sale size of 13,494 shares, suggesting a potential for further material sales [8]

Core Insights - Harmony Biosciences has shown promising financial performance, but the CFO, Sandip Kapadia, sold all her direct equity ownership in January 2026, raising questions about insider sentiment [1][6]. Financial Overview - As of January 31, 2026, Harmony Biosciences' stock price was $35.52, with a market capitalization of $2.1 billion, revenue of $825.94 million, and net income of $185.68 million [4]. - The transaction involved the sale of 20,961 shares for approximately $752,800, executed at a weighted average price of $35.92 per share [2][9]. Company Profile - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for treating narcolepsy [5]. Future Outlook - The company anticipates over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [7]. - Other medications in advanced development stages are projected to sustain revenue generation into 2040, with a 10% increase in 2025 [8]. Insider Trading Context - Kapadia's sale fully liquidated her direct holdings, which had previously been reduced from 72,948 shares to zero over the past year [9]. - The sale price was slightly below the market close of $36.41 on the transaction date and below the current share price of $36.62 as of January 31, 2026 [9].

Core Insights - The article discusses four stocks that exemplify the GARP (Growth at a Reasonable Price) investment strategy, highlighting their attractive PEG ratios and strong growth outlooks. Group 1: GARP Investment Strategy - GARP investing combines growth and value investing principles, aiming for stocks that are undervalued yet have solid growth potential [4][6]. - The PEG ratio, which is the price-to-earnings ratio divided by the earnings growth rate, is a key metric for GARP investors, with a lower PEG ratio (preferably less than 1) indicating better investment potential [6][7]. Group 2: Stock Analysis - **Nexa Resources**: A global zinc miner with a Zacks Rank of 2 and a Value Score of A, it has a long-term expected growth rate of 35.6% and a discounted PEG and P/E ratio [11]. - **Harmony Biosciences**: A U.S.-based pharmaceutical company with a Zacks Rank of 1 and a Value Score of A, it has a five-year expected growth rate of 27.1% [12]. - **Commercial Metals**: This company, which manufactures and recycles steel and metal products, has a Zacks Rank of 2 and a Value Score of A, with a long-term expected growth rate of 25.5% [14]. - **Suzano**: A manufacturer of pulp and paper products with a Zacks Rank of 1 and a Value Score of A, it boasts a solid long-term expected growth rate of 44.1% [16].

Core Viewpoint - Harmony Biosciences is entering 2026 with significant momentum driven by three key factors: strong performance of WAKIX, a robust late-stage pipeline, and a strong financial profile [3][4]. Group 1: WAKIX Performance - WAKIX has shown five years of consecutive growth and profitability, with guidance for 2026 indicating over $1 billion in net revenue, positioning it to achieve blockbuster status this year [3]. Group 2: Late-Stage Pipeline - The company has five Phase III programs in the clinic targeting five distinct CNS indications, which are expected to provide multiple catalysts in the coming years [4]. Group 3: Financial Profile - Harmony Biosciences is characterized by a strong financial profile, indicating profitability and a solid foundation for future growth [4].

Harmony Biosciences FY Conference Summary Company Overview - **Company**: Harmony Biosciences (NasdaqGM:HRMY) - **Event**: 44th JPM Healthcare Conference - **Date**: January 13, 2026 Key Industry Insights - **Core Focus**: Central Nervous System (CNS) disorders, particularly narcolepsy and related conditions - **Product Highlight**: WAKIX, a treatment for narcolepsy, is on track to achieve blockbuster status in 2026 with projected net revenue exceeding $1 billion Core Points and Arguments 1. **Momentum and Growth**: Harmony enters 2026 with significant momentum driven by three key factors: WAKIX performance, a robust late-stage pipeline, and a strong financial profile [2][3] 2. **WAKIX Performance**: WAKIX has shown five years of consecutive growth and profitability, with 2025 net revenue reported at $868 million, exceeding guidance [9][41] 3. **Pipeline Development**: Five phase three programs are advancing towards distinct CNS indications, setting up multiple catalysts for growth in the coming years [2][24] 4. **Pitolisant Franchise Expansion**: The introduction of Pitolisant GR (gastro-resistant formulation) and Pitolisant HD (high-dose formulation) aims to address unmet patient needs and expand the franchise [4][13] 5. **Market Opportunity**: There are approximately 80,000 diagnosed narcolepsy patients in the US, with an additional 90,000 undiagnosed, indicating significant growth potential for WAKIX [10][42] 6. **Commercial Strategy**: Harmony has improved its commercial operations, achieving broad formulary access (80% of lives covered) and enhancing patient support systems [11][27] 7. **Regulatory Milestones**: Anticipated NDA submission for Pitolisant GR in Q2 2026, with a PDUFA date expected in Q1 2027 [30][37] 8. **Financial Health**: Harmony maintains a strong balance sheet with over $770 million in cash, allowing for continued investment in pipeline development and business growth [44][45] Additional Important Insights - **Patient-Centric Approach**: The company emphasizes the importance of addressing patient needs, particularly in narcolepsy and related disorders, through innovative product formulations [4][14] - **Unique Product Profiles**: The differentiated profiles of Pitolisant formulations are expected to enhance clinical utility and market competitiveness [6][39] - **Future Catalysts**: Anticipated data readouts from ongoing trials in 2027 and 2028 for various CNS indications, including Prader-Willi syndrome and epilepsy programs [21][20] - **Business Development Focus**: Harmony is actively seeking strategic opportunities to expand its portfolio in the CNS space, particularly in orphan and rare diseases [44][45] This summary encapsulates the key points discussed during the conference, highlighting Harmony Biosciences' strategic direction, product pipeline, and market opportunities within the CNS industry.